Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
Resource
J. Clin. Oncol., 33(15),
Journal
J. Clin. Oncol.
Journal Volume
33
Journal Issue
15
Pages
-
Date Issued
2015
Date
2015
Author(s)
Yang, James Chih-Hsin
Ahn, Myung-Ju
Dickgreber, Nicolas J.
Halmos, Balazs
Hirsh, Vera
Hochmair, Maximilian J.
Levy, Benjamin Philip
De Marinis, Filippo
Mok, Tony
O'Byrne, Kenneth
Okamoto, Isamu
Schuler, Martin H.
Sebastian, Martin
Shah, Riyaz N. H.
Tan, Eng-Huat
Yamamoto, Nobuyuki
Marten, Angela
Massey, Dan
Wind, Sven
Carbone, David Paul
SDGs